載入...
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
BACKGROUND: Ipilimumab improves survival in patients with advanced melanoma. The activity and safety of ipilimumab outside of a clinical trial was assessed in an expanded access programme (EAP). METHODS: Ipilimumab was available upon physician request for patients aged 16 or over with pretreated sta...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BioMed Central
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4030525/ https://ncbi.nlm.nih.gov/pubmed/24885479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-12-116 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|